Christiane Knoop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christiane Knoop has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Marc Estenne
Chest Service, Erasme University Hospital, 808 Route de Lennik, B-1070 Brussels, Belgium
9 shared publications B. Rondelet
Unite de Transplantation Cardiaque et Pulmonaire, Université Libre de Bruxelles, Brussel, Belgium
5 shared publicationsM. Dumonceaux
4 shared publicationsJ C Yernault
3 shared publicationsM Antoine
3 shared publicationsA De Troyer
1 shared publication
Latest Publications
- 1 April 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (4) , S30
Differential Airway Involvement in Restrictive Phenotypes of Chronic Lung Allograft Dysfunction
- 1 April 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (4) , S30
Differential Airway Involvement in Restrictive Phenotypes of Chronic Lung Allograft Dysfunction
- 1 April 2012
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (4) , S98-S99
273 Seroconversion and Safety of H1N1 Vaccination in Lung Transplant Recipients: Data from the Brussels Lung Transplant Group
- 1 April 2012
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (4) , S98-S99
273 Seroconversion and Safety of H1N1 Vaccination in Lung Transplant Recipients: Data from the Brussels Lung Transplant Group
- 1 February 2010
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 67 (1) , 28-49
Complications non chirurgicales de la transplantation pulmonaire
- 1 February 2010
- Published by Elsevier in Revue de Pneumologie Clinique
- Vol. 67 (1) , 28-49
Complications non chirurgicales de la transplantation pulmonaire
- Open Access
- 1 January 2010
- Published by Springer Nature in BMC Microbiology
- Vol. 10 (1) , 245
Comparison of culture and qPCR for the detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients
Pseudomonas aeruginosa is the major respiratory pathogen causing severe lung infections among CF patients, leading to high morbidity and mortality. Once infection is established, early antibiotic treatment is able to postpone the transition to chronic lung infection. In order to optimize the early detection, we compared the sensitivity of microbiological culture and quantitative PCR (qPCR) for the detection of P. aeruginosa in respiratory samples of not chronically infected CF patients. In this national study, we followed CF patients during periods between 1 to 15 months. For a total of 852 samples, 729 (86%) remained P. aeruginosa negative by both culture and qPCR, whereas 89 samples (10%) were positive by both culture and qPCR. Twenty-six samples were negative by culture but positive by qPCR, and 10 samples were positive by culture but remained negative by qPCR. Five of the 26 patients with a culture negative, qPCR positive sample became later P. aeruginosa positive both by culture and qPCR. Based on the results of this study, it can be concluded that qPCR may have a predictive value for impending P. aeruginosa infection for only a limited number of patients.
- 1 January 2010
- Published by Springer Nature in BMC Microbiology
- Vol. 10 (1) , 245
Open AccessComparison of culture and qPCR for the detection of Pseudomonas aeruginosa in not chronically infected cystic fibrosis patients
Pseudomonas aeruginosa is the major respiratory pathogen causing severe lung infections among CF patients, leading to high morbidity and mortality. Once infection is established, early antibiotic treatment is able to postpone the transition to chronic lung infection. In order to optimize the early detection, we compared the sensitivity of microbiological culture and quantitative PCR (qPCR) for the detection of P. aeruginosa in respiratory samples of not chronically infected CF patients. In this national study, we followed CF patients during periods between 1 to 15 months. For a total of 852 samples, 729 (86%) remained P. aeruginosa negative by both culture and qPCR, whereas 89 samples (10%) were positive by both culture and qPCR. Twenty-six samples were negative by culture but positive by qPCR, and 10 samples were positive by culture but remained negative by qPCR. Five of the 26 patients with a culture negative, qPCR positive sample became later P. aeruginosa positive both by culture and qPCR. Based on the results of this study, it can be concluded that qPCR may have a predictive value for impending P. aeruginosa infection for only a limited number of patients.
- 1 October 2009
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 14 (5) , 466-470
Disease-specific approach to lung transplantation
The present review provides an update on the recent literature regarding disease-specific issues in lung transplantation. Some of the published data will help refine previously published candidate selection criteria and provide evidence-based data for choice of procedures. Recent studies on lung transplant outcomes in older patients underline that satisfactory results can be obtained in patients older than 60 years but not in patients older than 70 years. Data from two large registry-based studies indicate that bilateral lung transplantation in patients with chronic obstructive pulmonary disease confers significantly longer survival than single lung transplantation, especially in patients younger than 60 years. Mathematical models to estimate survival benefit in chronic obstructive pulmonary disease lung transplant candidates have been developed and are being validated. The impact of Bcc colonization in cystic fibrosis patients on outcome has been nuanced; thus, cystic fibrosis lung transplant candidates colonized by particular Bcc strains may be transplanted with good outcomes. Novel surgical approaches to peculiar situations in end-stage cystic fibrosis have been described. Candidate selection criteria for retransplantation procedures have further been clarified. This article attempts to provide an overview of some of the currently important topics for clinicians involved in referring and evaluating patients with end-stage lung disease for lung transplantation in 2009.
- 1 October 2009
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 14 (5) , 466-470
Disease-specific approach to lung transplantation
The present review provides an update on the recent literature regarding disease-specific issues in lung transplantation. Some of the published data will help refine previously published candidate selection criteria and provide evidence-based data for choice of procedures. Recent studies on lung transplant outcomes in older patients underline that satisfactory results can be obtained in patients older than 60 years but not in patients older than 70 years. Data from two large registry-based studies indicate that bilateral lung transplantation in patients with chronic obstructive pulmonary disease confers significantly longer survival than single lung transplantation, especially in patients younger than 60 years. Mathematical models to estimate survival benefit in chronic obstructive pulmonary disease lung transplant candidates have been developed and are being validated. The impact of Bcc colonization in cystic fibrosis patients on outcome has been nuanced; thus, cystic fibrosis lung transplant candidates colonized by particular Bcc strains may be transplanted with good outcomes. Novel surgical approaches to peculiar situations in end-stage cystic fibrosis have been described. Candidate selection criteria for retransplantation procedures have further been clarified. This article attempts to provide an overview of some of the currently important topics for clinicians involved in referring and evaluating patients with end-stage lung disease for lung transplantation in 2009.
- 1 June 2009
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 26 (6) , 704
Complications de la transplantation pulmonaire : complications péri-opératoires, rejet aigu et chronique.
- 1 June 2009
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 26 (6) , 704
Complications de la transplantation pulmonaire : complications péri-opératoires, rejet aigu et chronique.
- 1 June 2009
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 26 (6) , 700
Complications de la transplantation pulmonaire : complications péri-opératoires, rejet aigu et chronique.
- 1 June 2009
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 26 (6) , 700
Complications de la transplantation pulmonaire : complications péri-opératoires, rejet aigu et chronique.
- Open Access
- 1 January 2003
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 23 (1) , 159-171
Immunosuppressive therapy after human lung transplantation
In 2002, equal numbers of lung transplantation (LTx) were performed with or without induction therapy with antilymphocyte antibodies, monoclonal anti-CD3 antibody or anti-interleukin‐2‐receptor monoclonal antibodies. It remains to be established if induction therapy after LTx is beneficial or deleterious for long-term graft and patient survival.The vast majority of lung transplant recipients receive a triple-drug maintenance regimen including a calcineurin inhibitor, a cell-cycle inhibitor and steroids. Equal proportions receive cyclosporin A (CsA) and tacrolimus (Tac). There is also a trend to prescribe mycophenolate mofetil (MMF) instead of azathioprine (Aza). Steroid withdrawal is uncommon even 5 yrs after transplantation.The superiority of Tac over CsA as a maintenance agent has not been established to date, and the administration of MMF instead of Aza in combination with CsA and steroids did not improve graft or patient survival in a recent international, prospective, randomised, controlled trial.Shift from cyclosporin A to tacrolimus has emerged as the first treatment step of refractory acute rejection followed by high-dose steroids or antilymphocyte agents, total lymphoid irradiation or photopheresis. The treatment of chronic rejection remains deceptive and includes varied strategies such as modification of the maintenance regimen, addition of inhaled immunosuppressants and/or total lymphoid irradiation and photopheresis.
- 1 January 2003
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 23 (1) , 159-171
Open AccessImmunosuppressive therapy after human lung transplantation
In 2002, equal numbers of lung transplantation (LTx) were performed with or without induction therapy with antilymphocyte antibodies, monoclonal anti-CD3 antibody or anti-interleukin‐2‐receptor monoclonal antibodies. It remains to be established if induction therapy after LTx is beneficial or deleterious for long-term graft and patient survival.The vast majority of lung transplant recipients receive a triple-drug maintenance regimen including a calcineurin inhibitor, a cell-cycle inhibitor and steroids. Equal proportions receive cyclosporin A (CsA) and tacrolimus (Tac). There is also a trend to prescribe mycophenolate mofetil (MMF) instead of azathioprine (Aza). Steroid withdrawal is uncommon even 5 yrs after transplantation.The superiority of Tac over CsA as a maintenance agent has not been established to date, and the administration of MMF instead of Aza in combination with CsA and steroids did not improve graft or patient survival in a recent international, prospective, randomised, controlled trial.Shift from cyclosporin A to tacrolimus has emerged as the first treatment step of refractory acute rejection followed by high-dose steroids or antilymphocyte agents, total lymphoid irradiation or photopheresis. The treatment of chronic rejection remains deceptive and includes varied strategies such as modification of the maintenance regimen, addition of inhaled immunosuppressants and/or total lymphoid irradiation and photopheresis.
- 1 January 2002
- p. 151-4
[The pneumology department].
The department of pneumology of the Erasme hospital exists since 25 years. The basic clinical activities include pulmonary function testing (7,500 patients per year), endoscopy, including interventional endoscopy (1,500 patients per year), thoracic oncology, allergology, rehabilitation and aid to smoking cessation. The following expertise fields have been largely developed: lung transplantation, treatment of cystic fibrosis in collaboration with the children's hospital Reine Fabiola, occupational.
- 1 January 2002
- p. 151-4
[The pneumology department].
The department of pneumology of the Erasme hospital exists since 25 years. The basic clinical activities include pulmonary function testing (7,500 patients per year), endoscopy, including interventional endoscopy (1,500 patients per year), thoracic oncology, allergology, rehabilitation and aid to smoking cessation. The following expertise fields have been largely developed: lung transplantation, treatment of cystic fibrosis in collaboration with the children's hospital Reine Fabiola, occupational.